文献速递消化系统肿瘤

首创药物CPI-613联合改良FOLFIRINOX治疗转移性胰腺癌的安全性与耐受性:单中心、开放标签、剂量递增1期试验

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
PubMed 文献 · Lancet Oncol · 2017-05-08

这项单中心、开放标签、剂量递增1期试验在20例初治转移性胰腺癌患者中确定CPI-613联合改良FOLFIRINOX的最大耐受剂量为500 mg/m2,18例在该剂量治疗的患者中11例(61%)达到客观缓解,常见3-4级非血液学不良事件为高血糖(10例[55%]),研究结论需2期试验验证。

要点

  • CPI-613联合改良FOLFIRINOX的最大耐受剂量为500 mg/m2。
  • 最大耐受剂量组18例中11例(61%)达到客观缓解。
  • 常见3-4级非血液学不良事件为高血糖(10例[55%])。

核心结论

  • CPI-613联合改良FOLFIRINOX治疗转移性胰腺癌的最大耐受剂量为500 mg/m2。
  • 临床活性发现需在2期试验中验证。

研究设计与样本

  • 单中心、开放标签、剂量递增1期试验,纳入20例初治转移性胰腺腺癌成人患者(≥18岁),ECOG体能状态0-1。
  • 采用两阶段剂量递增方案(单患者阶段和传统3+3设计),CPI-613起始剂量500 mg/m2/天,若4周内无与CPI-613可能或肯定相关的2级以上不良事件则剂量加倍。
  • 改良FOLFIRINOX方案:奥沙利铂65 mg/m2、亚叶酸钙400 mg/m2、伊立替康140 mg/m2、氟尿嘧啶400 mg/m2推注后2400 mg/m2持续46小时。
  • 主要目标为确定CPI-613的最大耐受剂量(通过剂量限制性毒性评估),试验注册号NCT01835041,已停止招募。

主要发现

  • 2013年4月22日至2016年1月8日共入组20例患者,CPI-613最大耐受剂量为500 mg/m2。
  • 在最大耐受剂量治疗的18例患者中,中位治疗周期数为11(IQR 4-19),中位随访378天(IQR 250-602)。
  • 2例入组1000 mg/m2更高剂量的患者均发生剂量限制性毒性。
  • 最大耐受剂量组18例中,最常见的3-4级非血液学不良事件为高血糖(10例[55%])、低钾血症(6例[33%])、外周感觉神经病(5例[28%])、腹泻(5例[28%])和腹痛(4例[22%])。
  • 最大耐受剂量组18例中,最常见的3-4级血液学不良事件为中性粒细胞减少(5例[28%])、淋巴细胞减少(5例[28%])、贫血(4例[22%])和血小板减少(3例[17%]);感觉神经病(均为1-3级)见于17例(94%),按标准治疗进行剂量下调或停药处理。

局限性

  • 原文结论指出临床活性发现需在2期试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic disease. Metabolic reprogramming is an emerging hallmark of pancreatic adenocarcinoma. CPI-613 is a novel anticancer agent that selectively targets the altered form of mitochondrial energy metabolism in tumour cells, causing changes in mitochondrial enzyme activities and redox status that lead to apoptosis, necrosis, and autophagy of tumour cells. We aimed to establish the maximum tolerated dose of CPI-613 when used in combination with modified FOLFIRINOX chemotherapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients with metastatic pancreatic cancer. METHODS: In this single-centre, open-label, dose-escalation phase 1 trial, we recruited adult patients (aged ≥18 years) with newly diagnosed metastatic pancreatic adenocarcinoma from the Comprehensive Cancer Center of Wake Forest Baptist Medical Center (Winston-Salem, NC, USA). Patients had good bone marrow, liver and kidney function, and good performance status (Eastern Cooperative Oncology Group [ECOG] performance status 0-1). We studied CPI-613 in combination with modified FOLFIRINOX (oxaliplatin at 65 mg/m2, leucovorin at 400 mg/m2, irinotecan at 140 mg/m2, and fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 h). We applied a two-stage dose-escalation scheme (single patient and traditional 3+3 design). In the single-patient stage, one patient was accrued per dose level. The starting dose of CPI-613 was 500 mg/m2 per day; the dose level was then escalated by doubling the previous dose if there were no adverse events worse than grade 2 within 4 weeks attributed as probably or definitely related to CPI-613. The traditional 3+3 dose-escalation stage was triggered if toxic effects attributed as probably or definitely related to CPI-613 were grade 2 or worse. The dose level for CPI-613 for the first cohort in the traditional dose-escalation stage was the same as that used in the last cohort of the single-patient dose-escalation stage. The primary objective was to establish the maximum tolerated dose of CPI-613 (as assessed by dose-limiting toxicities). This trial is registered with ClinicalTrials.gov, number NCT01835041, and is closed to recruitment. FINDINGS: Between April 22, 2013, and Jan 8, 2016, we enrolled 20 patients. The maximum tolerated dose of CPI-613 was 500 mg/m2. The median number of treatment cycles given at the maximum tolerated dose was 11 (IQR 4-19). Median follow-up of the 18 patients treated at the maximum tolerated dose was 378 days (IQR 250-602). Two patients enrolled at a higher dose of 1000 mg/m2, and both had a dose-limiting toxicity. Two unexpected serious adverse events occurred, both for the first patient enrolled. Expected serious adverse events were: thrombocytopenia, anaemia, and lymphopenia (all for patient number 2; anaemia and lymphopenia were dose-limiting toxicities); hyperglycaemia (in patient number 7); hypokalaemia, hypoalbuminaemia, and sepsis (patient number 11); and neutropenia (patient number 20). No deaths due to adverse events were reported. For the 18 patients given the maximum tolerated dose, the most common grade 3-4 non-haematological adverse events were hyperglycaemia (ten [55%] patients), hypokalaemia (six [33%]), peripheral sensory neuropathy (five [28%]), diarrhoea (five [28%]), and abdominal pain (four [22%]). The most common grade 3-4 haematological adverse events were neutropenia (five [28%] of 18 patients), lymphopenia (five [28%]), anaemia (four [22%], and thrombocytopenia in three [17%]). Sensory neuropathy (all grade 1-3) was recorded in 17 (94%) of the 18 patients and was managed with dose de-escalation or discontinuation per standard of care. No patients died while on active treatment; 11 study participants died, with cause of death as terminal pancreatic cancer. Of the 18 patients given the maximum tolerated dose, 11 (61%) achieved an objective (complete or partial) response. INTERPRETATION: A maximum tolerated dose of CPI-613 was established at 500 mg/m2 when used in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer. The findings of clinical activity will require validation in a phase 2 trial. FUNDING: Comprehensive Cancer Center of Wake Forest Baptist Medical Center.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Alistar A, Morris BB, Desnoyer R, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017. PMID: 28495639. doi:10.1016/S1470-2045(17)30314-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。